Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) disclosed a share buyback on 17 June 2026, aimed at its A-share Employee Stock Ownership Schemes (ESOP).

• Transaction details: 120,000 A shares were repurchased on the Shanghai Stock Exchange at prices between RMB 46.85 and RMB 46.88 per share, representing a volume-weighted average price of RMB 46.87. The aggregate consideration amounted to RMB 5.62 million.

• Impact on share capital: Following the repurchase, issued shares (excluding treasury shares) fell from 6,370.81 million to 6,370.69 million, a marginal 0.0019% reduction. Treasury shares increased to 8.31 million, keeping total issued shares unchanged at 6,379.00 million.

• Purpose and status: All 120,000 repurchased shares are held as treasury stock for the ESOP. No cancellations were reported.

• Compliance: The company confirmed the buyback was duly authorised by the board and conducted in accordance with all applicable listing rules, laws and regulatory requirements.